Overexpression of Wnt ligands and treatment of lytic bone diseases
View Patent ↗The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy. The individuals who might benefit from such method may include but are not limited to the ones with multiple myeloma, osteoporosis, post-menopausal osteoporosis, fractures, metastatic breast cancer or metastatic prostate cancer.
1. A method of repairing or treating lytic bone lesions in an individual with multiple myeloma, comprising:
expressing Wnt-3a in said individual; and
blocking the activity of the human homologue of Dickkopf-1 (DKK1), wherein the activity of the human homologue of DKK1 is blocked prior to, concurrent with or subsequent to said expression of the Wnt-3a ligand.
2. The method of claim 1 , wherein the expression of Wnt-3a in combination with the blocked activity of the human homologue of DKK1 induces bone anabolic effects in the individual and inhibits tumor growth in the bone.
3. The method of claim 2 , wherein the analobic effects comprise inhibition of osteolysis and increasing bone mineral density.
4. The method of claim 1 , wherein the activity of the human homologue of DKK1 is blocked by administering anti-DKK1 antibodies.
5. The method of claim 1 , wherein the Wnt-3a is expressed by over-expressing a gene encoding Wnt-3a.
6. The method of claim 1 , wherein the Wnt-3a is expressed by administering pharmacologically effective amounts of the gene encoding the Wnt-3a directly into the lytic site or by local and/or systemic pulsing for short period of time or by pretreating osteoblast precursor cells with the gene encoding the Wnt-3a for several hours ex-vivo and then injecting the treated precursor cells into the lytic site.
7. The method of claim 1 , wherein the gene is delivered by a viral vector or a non-viral gene delivery system.
8. The method of claim 7 , wherein the viral vector is an adenoviral vector or a lentiviral vector.
9. The method of claim 7 , wherein the non-viral gene delivery system is liposome or a high-pressure gene delivery system.
10. A method of preventing or reducing bone destruction in an individual with multiple myeloma, comprising:
administering pharmacologically effective amounts of Wnt-3a to said individual, wherein said Wnt-3a increases ratio of ostoeblast to osteoclast and bone mineral density, thereby preventing or reducing bone destruction in the individual;
administering pharmacologically effective amounts of a compound that blocks the activity of the human homologue of Dickkopf-1 (DKK1), wherein the activity of the human homologue of DKK1 is blocked prior to, concurrent with or subsequent to said expression of the Wnt-3a.
11. The method of claim 10 , further comprising:
controlling tumor growth in the bone of the individual.
12. The method of claim 10 , wherein the compound is an anti-DKK1 antibody.
13. The method of claim 10 , wherein the Wnt-3a ligand is administered as a gene encoding Wnt-3a.
14. The method of claim 13 , wherein the gene encoding the Wnt-3a is directly administered into the lytic site or pulsed systemically and/or locally for short periods of time or indirectly administered by pretreating osteoblast precursor cells with the gene encoding the Wnt-3a for several hours ex-vivo and the injecting the treated precursor cells into the lytic site.
15. The method of claim 13 , wherein the gene is delivered by a viral vector or a non-viral gene delivery system.
16. The method of claim 15 , wherein the viral vector is an adenoviral vector or lentiviral vector.
17. The method of claim 15 , wherein the non-viral gene delivery system is liposome or a high-pressure gene delivery system.
18. A method of inhibiting progression of a tumor in the bone of an individual with multiple myeloma, comprising:
administering pharmacologically effective amounts of Wnt-3a ligand to said individual, in an amount that prevents bone destruction and inhibits growth of the tumor, thereby inhibiting progression of the tumor in the bone of the individual; and
administering pharmacologically effective amounts of a compound that blocks the activity of the human homologue of DKK1, wherein the activity of the human homologue of DKK1 is blocked prior to, concurrent with or subsequent to said expression of the Wnt-3a ligand.
19. The method of claim 18 , wherein the compound is an anti-DKK1 antibody.
20. The method of claim 18 , wherein the Wnt-3a ligand is administered as a gene encoding the Wnt-3a ligand.
21. The method of claim 20 , wherein the gene encoding the Wnt-3a ligand is directly administered into a lesion on the bone or pulsed systemically and/or locally for short periods of time or indirectly administered by pretreating osteoblast precursor cells with the gene encoding the Wnt-3a ligand for several hours ex-vivo and then injecting the treated precursor cells into the lytic site.
22. The method of claim 20 , wherein the gene is delivered by a viral vector or a non-viral gene delivery system.
23. The method of claim 22 , wherein the viral vector is an adenoviral vector or a lentiviral vector.
24. The method of claim 22 , wherein the non-viral gene delivery system is liposome or a high-pressure gene delivery system.